Leli Zeng

5.7k total citations · 6 hit papers
79 papers, 4.6k citations indexed

About

Leli Zeng is a scholar working on Molecular Biology, Oncology and Biomedical Engineering. According to data from OpenAlex, Leli Zeng has authored 79 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Molecular Biology, 34 papers in Oncology and 20 papers in Biomedical Engineering. Recurrent topics in Leli Zeng's work include Nanoplatforms for cancer theranostics (19 papers), Metal complexes synthesis and properties (15 papers) and Drug Transport and Resistance Mechanisms (13 papers). Leli Zeng is often cited by papers focused on Nanoplatforms for cancer theranostics (19 papers), Metal complexes synthesis and properties (15 papers) and Drug Transport and Resistance Mechanisms (13 papers). Leli Zeng collaborates with scholars based in China, United States and Hong Kong. Leli Zeng's co-authors include Zhe‐Sheng Chen, Hui Chao, Liang‐Nian Ji, Pranav Gupta, Yanglu Chen, Enju Wang, Yu Chen, Yihang Pan, Chengzhi Jin and Zi‐Ning Lei and has published in prestigious journals such as Chemical Society Reviews, Advanced Materials and Angewandte Chemie International Edition.

In The Last Decade

Leli Zeng

76 papers receiving 4.5k citations

Hit Papers

The development of anticancer ruthenium(ii) complexes: fr... 2017 2026 2020 2023 2017 2022 2023 2023 2022 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials
    2017 876 citations Leli Zeng, Pranav Gupta et al. Chemical Society Reviews profile →
  2. An Enzyme‐Engineered Nonporous Copper(I) Coordination Polymer Nanoplatform for Cuproptosis‐Based Synergistic Cancer Therapy
    2022 323 citations Yuzhi Xu, Si‐Yang Liu et al. Advanced Materials profile →
  3. Advancements in nanoparticle-based treatment approaches for skin cancer therapy
    2023 225 citations Leli Zeng, Zhe‐Sheng Chen et al. Molecular Cancer profile →
  4. Understanding and targeting resistance mechanisms in cancer
    2023 177 citations Zi‐Ning Lei, Tian Qin et al. SHILAP Revista de lepidopterología profile →
  5. Signaling pathways and therapeutic interventions in gastric cancer
    2022 167 citations Zi‐Ning Lei, Qiu‐Xu Teng et al. Signal Transduction and Targeted Therapy profile →
  6. Exosome circATP8A1 induces macrophage M2 polarization by regulating the miR-1-3p/STAT6 axis to promote gastric cancer progression
    2024 82 citations Mingyu Huo, Leli Zeng et al. Molecular Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leli Zeng China 33 1.7k 1.7k 1.4k 1.1k 1.0k 79 4.6k
Patrycja Nowak‐Sliwinska Switzerland 39 1.9k 1.1× 1.8k 1.0× 1.1k 0.8× 649 0.6× 945 0.9× 101 5.0k
Cai‐Ping Tan China 49 2.6k 1.5× 2.8k 1.6× 1.8k 1.3× 2.0k 1.8× 2.3k 2.2× 105 6.8k
Johannes Karges China 37 1.0k 0.6× 1.2k 0.7× 2.6k 1.9× 2.0k 1.9× 1.1k 1.1× 121 4.8k
Qian Cao China 40 2.2k 1.3× 538 0.3× 1.1k 0.8× 1.7k 1.6× 574 0.6× 153 5.5k
Аlexander А. Shtil Russia 33 2.3k 1.3× 938 0.5× 539 0.4× 614 0.6× 772 0.8× 255 4.4k
Yangzhong Liu China 40 2.1k 1.2× 1.2k 0.7× 1.6k 1.1× 1.7k 1.6× 724 0.7× 165 5.2k
Michael P. Hay New Zealand 32 2.9k 1.7× 873 0.5× 1.3k 1.0× 553 0.5× 998 1.0× 103 5.8k
Pranav Gupta United States 29 1.8k 1.0× 2.1k 1.3× 413 0.3× 337 0.3× 702 0.7× 77 3.9k
Huaiyi Huang China 36 1.3k 0.7× 1.5k 0.9× 2.3k 1.6× 2.4k 2.1× 1.5k 1.5× 101 4.9k
Liang He China 31 1.1k 0.6× 965 0.6× 905 0.7× 958 0.9× 790 0.8× 82 3.2k

Countries citing papers authored by Leli Zeng

Since Specialization
Citations

This map shows the geographic impact of Leli Zeng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leli Zeng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leli Zeng more than expected).

Fields of papers citing papers by Leli Zeng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leli Zeng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leli Zeng. The network helps show where Leli Zeng may publish in the future.

Co-authorship network of co-authors of Leli Zeng

This figure shows the co-authorship network connecting the top 25 collaborators of Leli Zeng. A scholar is included among the top collaborators of Leli Zeng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leli Zeng. Leli Zeng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tian, Qin, Jinxiang Wang, Qiji Li, et al.. (2025). Branched‐Chain α Keto‐Acid Dehydrogenase Kinase‐Mediated AKT Phosphorylation Promotes RCC Tumorigenesis and Drug Resistance. Advanced Science. 12(40). e11081–e11081.
2.
Yin, Songcheng, Huifang Liu, Zhijun Zhou, et al.. (2023). PUM1 Promotes Tumor Progression by Activating DEPTOR‐Meditated Glycolysis in Gastric Cancer. Advanced Science. 10(27). e2301190–e2301190. 17 indexed citations
3.
Xu, Shengshan, Hongyu Chu, Shuo Fang, et al.. (2023). Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2. Frontiers in Immunology. 14. 1155182–1155182. 16 indexed citations
4.
Li, Bo, Hui Chen, Shaohua Yang, et al.. (2023). Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers. Molecular Cancer. 22(1). 71–71. 24 indexed citations
5.
Lei, Zi‐Ning, Tian Qin, Qiu‐Xu Teng, et al.. (2023). Understanding and targeting resistance mechanisms in cancer. SHILAP Revista de lepidopterología. 4(3). e265–e265. 177 indexed citations breakdown →
6.
Xu, Yuzhi, Si‐Yang Liu, Leli Zeng, et al.. (2022). An Enzyme‐Engineered Nonporous Copper(I) Coordination Polymer Nanoplatform for Cuproptosis‐Based Synergistic Cancer Therapy. Advanced Materials. 34(43). e2204733–e2204733. 323 indexed citations breakdown →
7.
Lei, Zi‐Ning, Qiu‐Xu Teng, Tian Qin, et al.. (2022). Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduction and Targeted Therapy. 7(1). 358–358. 167 indexed citations breakdown →
8.
9.
Liu, Xinyu, Jing‐Quan Wang, Charles R. Ashby, et al.. (2021). Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer. Drug Discovery Today. 26(5). 1284–1292. 92 indexed citations
10.
Wu, Zhuo‐Xun, Yuqi Yang, Jing‐Quan Wang, et al.. (2021). Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells. Biomedicine & Pharmacotherapy. 136. 111223–111223. 17 indexed citations
11.
Li, Jia, Leli Zeng, Zheng Wang, et al.. (2021). Cycloruthenated Self‐Assembly with Metabolic Inhibition to Efficiently Overcome Multidrug Resistance in Cancers. Advanced Materials. 34(1). e2100245–e2100245. 46 indexed citations
12.
Liu, Kaisheng, Lin Gao, Xiaoshi Ma, et al.. (2020). Long non-coding RNAs regulate drug resistance in cancer. Molecular Cancer. 19(1). 54–54. 144 indexed citations
13.
Wang, Jing‐Quan, Qiu‐Xu Teng, Zi‐Ning Lei, et al.. (2020). Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells. Cancers. 12(2). 466–466. 48 indexed citations
14.
Zhang, Guan-Nan, Pranav Gupta, Ming Wang, et al.. (2020). Lipid–Saporin Nanoparticles for the Intracellular Delivery of Cytotoxic Protein to Overcome ABC Transporter-Mediated Multidrug Resistance In Vitro and In Vivo. Cancers. 12(2). 498–498. 11 indexed citations
15.
Song, Huibin, Dongcheng Liu, Shaowei Dong, et al.. (2020). Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. Signal Transduction and Targeted Therapy. 5(1). 193–193. 96 indexed citations
16.
Zeng, Leli, Jia Li, Chen Zhang, et al.. (2019). An organoruthenium complex overcomes ABCG2-mediated multidrug resistance via multiple mechanisms. Chemical Communications. 55(26). 3833–3836. 12 indexed citations
17.
Fan, Yingfang, Wei Zhang, Leli Zeng, et al.. (2018). Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Cancer Letters. 421. 186–198. 96 indexed citations
18.
Guan, Ruilin, Yu Chen, Leli Zeng, et al.. (2018). Oncosis-inducing cyclometalated iridium(iii) complexes. Chemical Science. 9(23). 5183–5190. 114 indexed citations
19.
Zeng, Leli, Pranav Gupta, Yanglu Chen, et al.. (2017). The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials. Chemical Society Reviews. 46(19). 5771–5804. 876 indexed citations breakdown →
20.
Zhang, Xiaoyu, Yunkai Zhang, Yi‐Jun Wang, et al.. (2016). Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells. Molecules. 21(9). 1236–1236. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patrycja Nowak‐Sliwinska Breakdown of academic impact, for papers by Cai‐Ping Tan Breakdown of academic impact, for papers by Johannes Karges Breakdown of academic impact, for papers by Qian Cao Breakdown of academic impact, for papers by Аlexander А. Shtil Breakdown of academic impact, for papers by Yangzhong Liu Breakdown of academic impact, for papers by Michael P. Hay Breakdown of academic impact, for papers by Pranav Gupta Breakdown of academic impact, for papers by Huaiyi Huang Breakdown of academic impact, for papers by Liang He
Rankless by CCL
2026